SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer.
Proteomics is more than just generating lists of proteins that increase or decrease in expression as a cause or consequence of pathology. The goal should be to characterize the information flow through the intercellular protein circuitry that communicates with the extracellular microenvironment and then ultimately to the serum/plasma macroenvironment. The nature of this information can be a cause, or a consequence, of disease and toxicity-based processes. Serum proteomic pattern diagnostics is a new type of proteomic platform in which patterns of proteomic signatures from high dimensional mass spectrometry data are used as a diagnostic classifier. This approach has recently shown tremendous promise in the detection of early-stage cancers. The biomarkers found by SELDI-TOF-based pattern recognition analysis are mostly low molecular weight fragments produced at the specific tumor microenvironment.
Petricoin
Emanuel F
EF
FDA-NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. petricoin@cber.fda.gov
Liotta
Lance A
LA
D000465:Algorithms; D001185:Artificial Intelligence; D014408:Biomarkers, Tumor / Q000097:blood* / Q000737:chemistry; D001774:Blood Chemical Analysis / Q000295:instrumentation / Q000379:methods; D004867:Equipment Design; D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D009363:Neoplasm Proteins / Q000097:blood* / Q000737:chemistry; D009369:Neoplasms / Q000097:blood* / Q000175:diagnosis*; D020539:Sequence Analysis, Protein / Q000379:methods*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000295:instrumentation* / Q000379:methods
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins